Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. Lithuania/
      2. How we work/
      3. Collaboration/
      4. New business development
      JJ_Photo_Colleagues in discussion at the office_IM_1Star.jpg

      New business development

      At Janssen we take pride in our track record of delivering new products to market including those that originated outside our organization. In addition to our own Research and Development (R&D), we have a history of successfully integrating licensed and partnered products, to create an innovative portfolio focused on delivering meaningful healthcare outcomes for patients. In our five focus therapeutic areas (below), we have established a leadership position through our product portfolio, deep market insights and best in class commercial capabilities.

      Building Strong, Long-Term Partnerships

      The New Business Development team builds strong, long-term collaborations that deliver added value to our partnered programs. Our ambition is to be considered the partner of choice. We already have more than 150 collaborations, across all aspects of the healthcare spectrum, including those with large pharmaceutical companies, biotech companies, academic institutions, public-private partnerships and open campus initiatives.

      Our Areas of Interest

      Our efforts are focused on five key therapeutic areas:

      • Cardiovascular & Metabolism
      • Immunology
      • Infectious Diseases & Vaccines
      • Neuroscience
      • Oncology

      Within these areas the EMEA New Business Development team is interested in partnerships around late stage development, registration or already marketed products. We are keen to discuss well-differentiated opportunities that will deliver value to our patients and will fit with our aspiration of being a transformational medical innovator.

      Collaborations have formed an essential part of our heritage and we are committed to working with our partners to achieve this goal.”
      Jane Griffiths
      Company Group Chairman, Janssen Europe, Middle East & Africa (EMEA)

      Extend Your Reach

      Our operational strength across the entire EMEA region – including Russia, Turkey and other Emerging Markets – will help you extend your reach to many more patients across the globe.

      Our team is distributed throughout the EMEA region and this in-depth knowledge of the markets enables us to accurately assess the value of an opportunity in rapidly evolving local market conditions.

      Contact Our Team

      If you would like to talk to us about your product or a partnership idea, please contact us today. We’ll ensure that you are connected with the appropriate person and that you receive a prompt reply: [email protected].

      Günter Huhle, MD, PhD, MSc
      Vice President, New Business Development & Mature Brands

      Chris Vaes, MSc, MBA
      Director, New Business Development, Emerging Markets, Therapeutic Areas

      Alexandr Krajhanzl, PhD
      Director, New Business Development, Mid-Size Markets; Franchise Lead, Infectious Diseases

      Marc de Hullu, MSc
      Executive Director, Alliance Management

      Letizia Goretti
      Director, Partnership Development

      Pierre Quelet, PhD, MBA
      Country Lead, France; Franchise Lead, Metabolics

      Laurence Mallick, MBA
      Country Lead, Spain; Franchise Lead, Neuroscience

      Filipa Costa, MSc, MBA
      Country Lead, Italy; Franchise Lead, Oncology

      Renier Van Dinter, MSc, MM
      Country Lead, Benelux; Franchise Lead, Cardiovascular

      Ahmed Mohamed, PhD, BSc
      Country Lead, UK; Franchise Lead, Immunology

      Marcus Stüttgen, MBA
      Country Lead, Germany; Franchise Lead, Vaccines